Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab vs Placebo Post-Radiotherapy in mCRPC
NCT00861614Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2009
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Ipilimumab with Placebo (2 arms). Primary endpoints: Overall Survival and Overall Survival Rate. Started May 2009; status: completed.
02
Drugs
ipilimumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00861614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00861614.